Joshua K. Sabari, MD

Joshua K. Sabari, MD, is an associate professor in the Department of Medicine at New York University (NYU) Grossman School of Medicine. He is also medical director, ofThoracic Medical Oncology at NYU Langone Health’s Perlmutter Cancer Center.

Articles by Joshua K. Sabari, MD

Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

BySandip Patel, MD,Heather Wakelee, MD,Joshua K. Sabari, MD,Aditya Juloori, MD

June 25th 2024

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

BySandip Patel, MD,Heather Wakelee, MD,Joshua K. Sabari, MD,Aditya Juloori, MD

June 25th 2024

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine

Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

ByJoshua K. Sabari, MD

March 29th 2024

Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.

Joshua K. Sabari, MD, an expert on lung cancer, presenting slides

Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study

ByJoshua K. Sabari, MD

February 26th 2024

Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.

Dr Sabari on the Potential Role for Patritumab Deruxtecan in NSCLC

ByJoshua K. Sabari, MD

February 9th 2024

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

A panel of 5 experts on lung cancer seated at a long table

Clinical Pearls and Future Perspectives in Advanced NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

January 3rd 2024

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

Future Perspectives in KRAS G12C-Mutated NSCLC

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

December 28th 2023

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.

Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

December 28th 2023

Shared insight on the clinical management of hepatotoxicity with use of KRAS G12C inhibitors in mNSCLC.

Antibody-Drug Conjugates in EGFR-Mutant NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

December 27th 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

December 27th 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

December 21st 2023

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

December 21st 2023

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.

Joshua K. Sabari, MD, and Marina Chiara Garassino, MD, experts on non-small cell lung cancer

Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

December 20th 2023

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

December 20th 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

December 15th 2023

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

December 15th 2023

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Disease Progression Beyond Frontline KRAS G12C Inhibitors

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

December 14th 2023

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

December 14th 2023

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

December 7th 2023

Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.

Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

December 7th 2023

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.

A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

December 6th 2023

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

December 6th 2023

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

Frontline Treatments for KRAS G12C-Mutation mNSCLC

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

November 30th 2023

Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.

The State of Targeted Therapies in NSCLC

ByJoshua K. Sabari, MD,Edward B. Garon, MD, MS

November 30th 2023

Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.

EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

November 29th 2023

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.

Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

November 29th 2023

The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.

Two experts on lung cancer seated at a table

TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

November 22nd 2023

Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.

NSCLC: PD-L1 Expression and Treatment Decision-Making

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

November 22nd 2023

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

The Role of CTLA-4 Inhibitors in NSCLC

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

November 15th 2023

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

ByBenjamin P. Levy, MD,Solange Peters, MD, PhD,Joshua K. Sabari, MD,Edward B. Garon, MD, MS,Marina Chiara Garassino, MD

November 15th 2023

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).

Joshua K. Sabari, MD

Articles by Joshua K. Sabari, MD

Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study

Dr Sabari on the Potential Role for Patritumab Deruxtecan in NSCLC

Clinical Pearls and Future Perspectives in Advanced NSCLC

Future Perspectives in KRAS G12C-Mutated NSCLC

Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

Antibody-Drug Conjugates in EGFR-Mutant NSCLC

MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

Disease Progression Beyond Frontline KRAS G12C Inhibitors

Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

Frontline Treatments for KRAS G12C-Mutation mNSCLC

The State of Targeted Therapies in NSCLC

EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

NSCLC: PD-L1 Expression and Treatment Decision-Making

The Role of CTLA-4 Inhibitors in NSCLC

First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

Trending on OncLive

FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer

Dana-Farber Study Finds Dual Immunotherapy May Help Certain Patients With Advanced NSCLC Live Longer